Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals submits NYSE American compliance plan on stockholders' equity

Neutral Impact 3 of 5 legal/regulatory Written later

Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026, describing actions management intends to take to restore compliance with listing standards. The exchange had notified the company on May 27, 2026 that its stockholders' equity was below the $4.0 million minimum required under Section 1003(a)(ii) of the NYSE American Company Guide, which applies after losses in three of four recent fiscal years.

Key points

  • June 18, 2026: Company submitted its compliance plan to NYSE American.
  • May 27, 2026: Company received the NYSE American notice regarding stockholders' equity.
  • Required minimum: stockholders' equity of $4.0 million or more under Section 1003(a)(ii).
  • The filing does not specify the individual actions management plans to take.

The filing

CompanyActinium Pharmaceuticals, Inc. (ATNM)
Form8-K, current report
Filed with the SECJun 18, 2026, 5:00 PM ET
Accession number0001213900-26-070193

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.